Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + BEAM for ASCT in Relapsed/Refractory NHL
NCT03713580Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in non-Hodgkin lymphoma (NHL), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Safety of intervention as defined by hematopoietic non-engraftment at 30 days. Started Mar 2019; status: completed.
02
Drugs
venetoclax
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03713580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713580.